痔瘡市場規模、佔有率和成長分析：按疾病、治療方法、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球痔瘡市場價值為 55.4 億美元，預計從 2025 年的 58 億美元成長到 2033 年的 83.6 億美元，在預測期（2026-2033 年）內複合年成長率為 4.68%。

全球痔瘡市場涵蓋針對痔瘡的藥品、醫療設備和非處方藥。痔瘡影響全球約15%的成年人。痔瘡的慢性病程和高復發率凸顯了其重要性，同時也推動了對微創治療的需求，以減少住院時間。人口老化是推動市場需求的主要因素，與老齡化相關的血管問題增加了痔瘡的盛行率，並大大拓展了治療選擇。這些人口結構的變化刺激了對創新醫療設備的投資，例如以減輕術後疼痛而聞名的冷凍消融導管。此外，製造商與胃腸病診所合作開發綜合診療方案，提供了廣泛的治療選擇，從而增加了藥品銷售以外的收入。人口老化、技術進步和綜合服務的融合，為市場上的成熟新興企業都帶來了巨大的成長潛力。

推動全球痔瘡市場發展的因素

由於久坐不動的生活方式、不健康的飲食習慣以及人們對消化器官系統健康意識的提高，成人痔瘡盛行率不斷上升，全球痔瘡市場因此蓬勃發展。這種意識的提高促使更多人因不適症狀尋求醫療協助，從而擴大了現有治療方案的潛在患者群體。隨著醫療專業人員採取更積極主動的方式來診斷痔瘡問題，對更多種類藥物和治療方法的需求也不斷成長。這一趨勢推動了市場成長，促使製造商不斷創新並拓展產品線，同時醫療機構也日益重視預防性篩檢和治療方案。

全球痔瘡市場的限制因素

全球痔瘡市場面臨許多挑戰，其中最主要的原因是人們對早期症狀的認知不足，阻礙了早期診斷。許多人雖然感到不適，卻並未尋求治療，導致患者數量下降，對現有治療方法的需求也隨之減少。不同族群的教育程度差異進一步加劇了這個問題，導致現有醫療保健解決方案的使用率不足，市場滲透率也隨之降低。此外，公共衛生宣傳活動往往未能有效涵蓋高風險族群，導致人們對預防措施和早期診斷的重要性缺乏認知，最終阻礙了市場整體成長和有效治療方法的廣泛應用。

全球痔瘡市場趨勢

全球痔瘡市場正經歷著向微創技術的顯著轉變，這從根本上改變了痔瘡治療的模式。臨床醫生越來越傾向於選擇能夠最大限度減少術後不適並加快患者康復的手術方式。諸如先進的橡皮筋結紮術、雷射凝固系統和射頻消融術等創新技術在門診治療中日益普及，簡化了治療流程，無需住院。這一轉變的驅動力源於患者對更短康復時間的日益成長的需求，以及醫療機構在確保高治療效果和提高患者滿意度的同時降低治療成本的努力，最終促使微創手術成為痔瘡治療的標準方法。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球痔瘡市場規模：依疾病類型分類

• 內痔
• 外痔
• 混合型痔瘡

全球痔瘡市場規模：依治療類型分類

• 保守治療（膳食纖維、軟便劑、生活方式調整）
• 藥物治療
  • 外用藥物
  • 口服藥物
  • 其他
• 微創手術
  • 橡皮筋結紮
  • 硬化療法
  • 紅外線凝固療法
  • 其他
• 手術治療
  • 切除術
  • 痔瘡釘固定術
  • 多普勒引導下痔動脈結紮術（DG-HAL）
  • 其他

全球痔瘡市場規模：依給藥途徑分類

• 外用
• 口服
• 注射藥物

全球痔瘡市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球痔瘡市場規模：依最終用戶分類

• 醫院
• 門診手術中心（ASC）
• 專科診所
• 居家醫療

全球痔瘡市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc
• Bayer AG
• Sanofi SA
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Viatris Inc
• Sandoz International GmbH
• Lupin Limited
• Cipla Limited
• Sun Pharmaceutical Industries Ltd
• Dr Reddys Laboratories Ltd
• Medtronic plc
• Cook Medical LLC
• Boston Scientific Corporation
• Stryker Corporation
• Teleflex Incorporated
• ConMed Corporation
• AstraZeneca plc

結論與建議

Global Hemorrhoids Market size was valued at USD 5.54 Billion in 2024 and is poised to grow from USD 5.8 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 4.68% during the forecast period (2026-2033).

The global hemorrhoids market encompasses pharmaceuticals, medical devices, and over-the-counter solutions targeting piles, which affect approximately fifteen percent of adults worldwide. The chronic nature of hemorrhoidal disease and high recurrence rates underpin its significance, alongside a growing preference for minimally invasive treatments that reduce hospital stays. The expanding aging population drives market demand, as age-related vascular issues increase hemorrhoidal cases, leading to a surge in therapeutic options. This demographic shift promotes investments in innovative devices, such as cryo-ablation catheters known for mitigating postoperative pain. Furthermore, partnerships between manufacturers and gastroenterology clinics to create bundled care pathways offer comprehensive treatment options, enhancing revenue beyond drug sales. This convergence of aging populations, technological advancements, and integrated services presents substantial growth potential for both established and emerging players in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemorrhoids market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemorrhoids Market Segments Analysis

Global hemorrhoids market is segmented by disease type, treatment type, route of administration, distribution channel, end user and region. Based on disease type, the market is segmented into Internal Hemorrhoids, External Hemorrhoids and Mixed Hemorrhoids. Based on treatment type, the market is segmented into Conservative Treatment (Dietary Fiber, Stool Softeners, Lifestyle Modification), Pharmacological Treatment, Minimally Invasive Procedures and Surgical Procedures. Based on route of administration, the market is segmented into Topical, Oral and Injectable. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemorrhoids Market

The global hemorrhoids market is experiencing growth due to the increasing prevalence of the condition among adults, influenced by factors such as sedentary lifestyles, unhealthy dietary choices, and heightened awareness regarding gastrointestinal health. This surge in awareness has led more individuals to seek medical attention for their discomfort, thereby broadening the potential patient base for available treatments. As healthcare professionals adopt proactive approaches to diagnose hemorrhoidal issues, there is a growing demand for various pharmaceutical and procedural interventions. This trend encourages manufacturers to innovate and expand their product offerings, while healthcare providers increasingly allocate resources toward preventive screenings and treatment options, further fueling market growth.

Restraints in the Global Hemorrhoids Market

The global hemorrhoids market faces significant challenges due to limited awareness of early symptoms, which hampers prompt diagnosis. Many individuals experience discomfort but do not seek treatment, resulting in a reduced patient pool and diminished demand for available therapies. This situation is exacerbated by educational gaps across different demographic groups, leading to the underutilization of existing medical solutions and slowing market penetration. Furthermore, public health campaigns often fail to effectively target high-risk populations, leaving them unaware of preventive measures and the importance of early evaluation, ultimately hindering overall market growth and adoption of effective treatments.

Market Trends of the Global Hemorrhoids Market

The Global Hemorrhoids market is witnessing a significant trend towards the adoption of minimally invasive technologies, fundamentally altering treatment paradigms. Clinicians are increasingly opting for procedures that minimize postoperative discomfort and expedite recovery for patients. Innovations such as advanced rubber band ligation, laser coagulation systems, and radiofrequency ablation are becoming commonplace in outpatient settings, streamlining care without the need for hospitalization. This shift is motivated by a growing patient preference for quicker recovery times and healthcare providers' efforts to reduce procedural costs while ensuring high therapeutic outcomes and enhanced patient satisfaction, ultimately positioning minimally invasive approaches as the standard of care in managing hemorrhoids.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hemorrhoids Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Internal Hemorrhoids
• External Hemorrhoids
• Mixed Hemorrhoids

Global Hemorrhoids Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Conservative Treatment (Dietary Fiber, Stool Softeners, Lifestyle Modification)
• Pharmacological Treatment
  • Topical Medications
  • Oral Medications
  • Others
• Minimally Invasive Procedures
  • Rubber Band Ligation
  • Sclerotherapy
  • Infrared Coagulation
  • Others
• Surgical Procedures
  • Hemorrhoidectomy
  • Stapled Hemorrhoidopexy
  • Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)
  • Others

Global Hemorrhoids Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Topical
• Oral
• Injectable

Global Hemorrhoids Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Hemorrhoids Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Home Care Settings

Global Hemorrhoids Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr Reddys Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ConMed Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations